Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

16.51EUR
12:35pm EDT
Change (% chg)

€-0.24 (-1.43%)
Prev Close
€16.75
Open
€16.40
Day's High
€16.71
Day's Low
€16.10
Volume
137,725
Avg. Vol
145,559
52-wk High
€19.90
52-wk Low
€9.09

Latest Key Developments (Source: Significant Developments)

AB Science announces positive results of final analysis from study AB10015
Monday, 20 Mar 2017 02:59am EDT 

AB Science SA : Announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS) . Phase 2/3 study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS) has met its pre-specified primary endpoint . This is the first successful phase 3 trial of a tyrosine kinase inhibitor in treatment of ALS . AB science filed an application for marketing authorization of masitinib in ALS at EMA in September 2016 .In accordance with study protocol, final analysis was performed based on 394 patients treated for 48-weeks.  Full Article

AB Science: phase 3 asthma fully enrolled
Monday, 6 Mar 2017 01:55am EST 

AB Science SA : Phase 3 asthma fully enrolled . Final results will be available at end of 2017 .A new phase 3 study has been initiated in asthma uncontrolled by high-dose inhaled corticosteroids and with elevated eosinophil level.  Full Article

AB Science H1 net loss widens to ‍​14.8 million euros
Wednesday, 31 Aug 2016 11:39am EDT 

AB Science SA : H1 net loss of ‍​14.8 million euros versus loss of 13.0 million euros ($14.49 million) year ago . H1 operating loss of ‍​16.1 million euros versus loss of 12.4 million euros year ago . H1 net revenue 0.8 million euros versus 1.3 million euros year ago .Cash position of 19.0 million euros at 30 june 2016 versus 17.1 million euros year ago.  Full Article

AB Science: Masitinib receives orphan drug designation in EU for ALS
Monday, 8 Aug 2016 11:42am EDT 

AB Science SA :Announces that Masitinib receives from European Medicines Agency (EMA) orphan drug designation in the European Union for Amyotrophic Lateral Sclerosis (ALS).  Full Article

AB Science announces FDA approval compassionate use of masitinib in amyotrophic lateral sclerosis
Monday, 11 Jul 2016 11:42am EDT 

AB Science SA :AB Science announces that FDA approves first compassionate use of masitinib in amyotrophic lateral sclerosis.  Full Article

AB Science submits to EMA the marketing authorization application for masitinib
Sunday, 1 May 2016 08:00pm EDT 

AB Science SA:Has submitted to EMA the marketing authorization application for masitinib in the treatment of severe systemic mastocytosis.Top-Line results from this phase 3 were previously announced on 30 November 2015.  Full Article

Ab Science announces success of a private placement
Sunday, 17 Apr 2016 08:00pm EDT 

AB Science SA:Announces success of a private placement.Twelve million euro raised through a private placement of 764,820 shares.Placement with subscription warrants to purchase an additional 191,205 shares attached at a price of 15.69 euro by way of an accelerated book-building.If all warrants are exercised, company would receive an additional 3.0 million euro of proceeds.  Full Article

Ab Science launches share capital increase
Saturday, 16 Apr 2016 08:00pm EDT 

AB Science SA:Said it launched a share capital increase by way of accelerated book building.The Private Placement is capped at 956,025 shares, to be issued immediately or following the exercise of any instrument giving access to the share capital.AB Science intends to use the net proceeds from the Private Placement for the funding of its general needs and to finance its clinical development program.The settlement date, on which the new ordinary shares will be delivered to the investors against payment, is expected to be April 20, 2016.  Full Article

AB Science announces positive interim results from phase 3 trial of masitinib
Sunday, 3 Apr 2016 08:00pm EDT 

AB Science SA:AB Science announces positive interim results from phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS).Predefined interim analysis has met its primary objective.Primary analysis was a success, with p-value < 0.01 in intention-to-treat (ITT) population.  Full Article

AB Science underscores potential of masitinib in neurological and neurodegenerative diseases
Thursday, 10 Mar 2016 11:45am EST 

AB Science SA:New independent publications underscore the potential of masitinib in neurological and neurodegenerative diseases.  Full Article

More From Around the Web

BRIEF-AB Science announces positive results of final analysis from study AB10015

* Announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)